These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 20373365)

  • 1. Inhibition of mammalian target of rapamycin: the janus face of immunosuppression?
    Soll C; Clavien PA
    Hepatology; 2010 Apr; 51(4):1113-5. PubMed ID: 20373365
    [No Abstract]   [Full Text] [Related]  

  • 2. [Liver transplantation for hepatocellular carcinoma and potential application of PSI].
    Decaens T; Duvoux C
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S257-62. PubMed ID: 20004332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma.
    Subbiah IM; Brown RE; Fallon MB
    Hepatology; 2010 Oct; 52(4):1524. PubMed ID: 20680964
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence.
    Schnitzbauer AA; Schlitt HJ; Geissler EK
    Transplantation; 2011 Jun; 91(11):1173-6. PubMed ID: 21427632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?
    Schwartz M; Roayaie S; Llovet J
    J Hepatol; 2005 Oct; 43(4):584-9. PubMed ID: 16120468
    [No Abstract]   [Full Text] [Related]  

  • 6. mTOR inhibition: the learning curve in kidney transplantation.
    Weir MR; Diekmann F; Flechner SM; Lebranchu Y; Mandelbrot DA; Oberbauer R; Kahan BD
    Transpl Int; 2010 May; 23(5):447-60. PubMed ID: 20136784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Indications of mTOR inhibitors in liver transplantation].
    Calmus Y; Dharancy S
    Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S245-6. PubMed ID: 20004329
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy after liver transplantation for hepatocellular carcinoma.
    Rizzi PM; Ryder SD; Ramage JK; Gane E; Karani J; Heaton N; Portmann B; Tan KC; Williams R
    Transplant Proc; 1994 Dec; 26(6):3568-9. PubMed ID: 7527979
    [No Abstract]   [Full Text] [Related]  

  • 9. Liver transplantation and hepatocellular carcinoma.
    Yokoyama I; Takagi H
    Semin Surg Oncol; 1996; 12(3):212-6. PubMed ID: 8727613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
    Bhatia S; Thompson JA
    Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
    Huynh H
    Cancer; 2010 Mar; 116(5):1315-25. PubMed ID: 20101735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B recurrence in relation to immunosuppression and acute allograft rejection.
    Platz KP; Mueller AR; Haller GW; Naumann U; Berg T; Fukomoto T; Lemmens HP; Hopf U; Lobeck H; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3236-7. PubMed ID: 8962252
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term follow-up in hepatitis C patients with respect to immunosuppression.
    Mueller AR; Platz KP; Berg T; Fukomoto T; Guckelberger O; Neuhaus R; Bechstein WO; Hopf U; Lobeck H; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3241-2. PubMed ID: 8962255
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of risk factors for recurrence of hepatocellular carcinoma after orthotopic liver transplantation.
    Lohmann R; Bechstein WO; Langrehr JM; Knoop M; Lobeck H; Keck H; Lemmems HP; Blumhardt G; Neuhaus P
    Transplant Proc; 1995 Feb; 27(1):1245-6. PubMed ID: 7533376
    [No Abstract]   [Full Text] [Related]  

  • 15. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?--no, never.
    Hiatt JR; Carmody IC; Busuttil RW
    J Hepatol; 2005 Oct; 43(4):573-7. PubMed ID: 16112768
    [No Abstract]   [Full Text] [Related]  

  • 16. Liver transplantation and hepatocellular carcinoma biology: beginning of the end of the era of educated guesses.
    Vauthey JN; Ajani JA
    J Clin Oncol; 2003 Dec; 21(23):4265-7. PubMed ID: 14581443
    [No Abstract]   [Full Text] [Related]  

  • 17. Should we expand the criteria for liver transplantation for hepatocellular carcinoma--yes, of course!
    Broelsch CE; Frilling A; Malago M
    J Hepatol; 2005 Oct; 43(4):569-73. PubMed ID: 16120470
    [No Abstract]   [Full Text] [Related]  

  • 18. Liver transplantation for hepatocellular carcinoma.
    Durand F; Belghiti J
    Hepatogastroenterology; 2002; 49(43):47-52. PubMed ID: 11941982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation for hepatocellular carcinoma: the Hangzhou experience.
    Busuttil RW
    Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):235-6. PubMed ID: 18522877
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunosuppression does not enhance tumor growth after orthotopic liver transplantation for hepatoma.
    Steininger R; Herbst F; Függer R; Mühlbacher F; Fritsch A
    Transplant Proc; 1992 Dec; 24(6):2690-2. PubMed ID: 1334597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.